THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT BY AND AMONG ZAFGEN, INC. AND THE INVESTORS NAMED HEREIN November 25, 2013Investors’ Rights Agreement • April 18th, 2014 • Zafgen, Inc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of November 25, 2013, by and between Zafgen, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any additional Investor that becomes a party to this Agreement in accordance with Section 6.9 hereof.
Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment AgreementEmployee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement • April 18th, 2014 • Zafgen, Inc. • Pharmaceutical preparations
In consideration and as a condition of my employment or continued employment by Zafgen, Inc. (the “Company”), 1 hereby agree as follows:
Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 EXCLUSIVE LICENSE AGREEMENT BETWEEN CHILDREN’S MEDICAL CENTER CORPORATION AND ZAFGEN, INC.Exclusive License Agreement • April 18th, 2014 • Zafgen, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement is made and entered into as of the date last written below (the “Effective Date”), by and between CHILDREN’S MEDICAL CENTER CORPORATION, a charitable corporation duly organized and existing under the laws of the Commonwealth of Massachusetts and having its principal office at 300 Longwood Avenue, Boston, Massachusetts 02115, U.S.A. (hereinafter referred to as “CMCC”), and Zafgen, Inc., a business corporation organized and existing under the laws of the State of Delaware and having its principal office at One Broadway, 14th Floor, Cambridge MA 02142 (hereinafter referred to as “Licensee”).
Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 18th, 2014 • Zafgen, Inc. • Pharmaceutical preparations
This Exclusive License Agreement (this “Agreement”), dated as of July 6, 2009 (the “Effective Date”), is made by and between Zafgen, Inc., a Delaware corporation (“Zafgen”), and Chong Kun Dang Pharmaceutical Corporation, a corporation organized under the laws of the Republic of Korea (“CKD”). CKD and Zafgen are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
Boston, MA 02116Employment Agreement • April 18th, 2014 • Zafgen, Inc. • Pharmaceutical preparations
This letter agreement (“Agreement”) will confirm our offer of employment with Zafgen (the “Company”) under the terms and conditions that follow:
